Shares of Baxter International Inc. (NYSE:BAX) have been assigned a consensus recommendation of “Buy” from the fifteen research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $65.69.

A number of research analysts recently issued reports on BAX shares. Royal Bank Of Canada reiterated a “hold” rating and issued a $60.00 price target on shares of Baxter International in a research note on Friday, September 1st. UBS AG lifted their price target on shares of Baxter International from $57.00 to $62.00 and gave the stock a “neutral” rating in a research note on Friday, July 28th. Barclays PLC lifted their price target on shares of Baxter International from $64.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. BidaskClub downgraded shares of Baxter International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Cowen and Company reissued a “market perform” rating and set a $66.00 price objective (up previously from $57.00) on shares of Baxter International in a report on Monday, July 10th.

COPYRIGHT VIOLATION WARNING: “Baxter International Inc. (BAX) Receives Average Recommendation of “Buy” from Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/11/baxter-international-inc-bax-receives-average-recommendation-of-buy-from-brokerages.html.

Baxter International (NYSE BAX) traded up 0.41% during trading on Wednesday, hitting $61.96. 164,542 shares of the company were exchanged. The stock’s 50-day moving average is $62.78 and its 200-day moving average is $59.18. Baxter International has a 12 month low of $43.13 and a 12 month high of $64.75. The company has a market capitalization of $33.76 billion, a price-to-earnings ratio of 35.82 and a beta of 0.65.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.06. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The business had revenue of $2.61 billion during the quarter, compared to analyst estimates of $2.59 billion. During the same quarter last year, the firm posted $0.46 earnings per share. The business’s revenue for the quarter was up .8% compared to the same quarter last year. Equities research analysts anticipate that Baxter International will post $2.39 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, October 2nd. Stockholders of record on Friday, September 1st were issued a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, August 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.04%. Baxter International’s payout ratio is 38.79%.

In related news, Director Thomas T. Stallkamp sold 8,920 shares of Baxter International stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $62.28, for a total value of $555,537.60. Following the transaction, the director now directly owns 16,263 shares in the company, valued at approximately $1,012,859.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Giuseppe Accogli sold 12,670 shares of Baxter International stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $60.96, for a total transaction of $772,363.20. Following the completion of the transaction, the senior vice president now owns 33,286 shares in the company, valued at $2,029,114.56. The disclosure for this sale can be found here. Insiders sold a total of 35,050 shares of company stock worth $2,158,587 over the last ninety days. Corporate insiders own 0.05% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Park National Corp OH grew its position in Baxter International by 18.9% in the 3rd quarter. Park National Corp OH now owns 10,969 shares of the medical instruments supplier’s stock valued at $688,000 after buying an additional 1,746 shares during the last quarter. Griffin Asset Management Inc. purchased a new stake in shares of Baxter International during the 2nd quarter worth $457,000. Achmea Investment Management B.V. boosted its position in shares of Baxter International by 15.3% during the 2nd quarter. Achmea Investment Management B.V. now owns 94,282 shares of the medical instruments supplier’s stock worth $5,706,000 after purchasing an additional 12,537 shares in the last quarter. USA Financial Portformulas Corp purchased a new stake in shares of Baxter International during the 2nd quarter worth $510,000. Finally, Farmers National Bank boosted its position in shares of Baxter International by 42.4% during the 2nd quarter. Farmers National Bank now owns 8,408 shares of the medical instruments supplier’s stock worth $509,000 after purchasing an additional 2,502 shares in the last quarter. Hedge funds and other institutional investors own 83.62% of the company’s stock.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.